Therapy in allergic rhinoconjunctivitis: new horizons

Abstract

Allergic Rhinitis (AR) is a common disease that impacts productivity and has significant patient morbidity. We have a variety of agents available for the treatment of AR, but numerous patients still lack good control of symptoms and some are tolerating undesired side effects. Surveys have shown 1/5 of patients with AR are not fully satisfied with their AR medications and almost 1/2 feel they receive insufficient attention from their physicians. Newer agents for the treatment of AR are in development, and an overview of some of these are presented here.